Weight-loss drugs show promise for painful skin condition, but caution advised

Hidradenitis suppurativa is a condition most people have never heard of, which makes it all the more isolating for those who live with it. The disease produces recurrent, painful lumps beneath the skin, typically in areas where the body folds—armpits, groin, under the breasts. It strikes women three times as often as men. For years, treatment options have been limited and often unsatisfying. But a recent study published in JAMA Dermatology has surfaced something unexpected: medications designed to help people lose weight and manage diabetes may also ease the symptoms of this stubborn skin condition.

The research came out of France and tracked 66 patients taking GLP-1 drugs—the class of medications that includes Ozempic and Wegovy—over an average of 18.5 months. Nearly 90 percent of the study participants also had diabetes, and their average body mass index was 39.4, placing them in the obese category. The results were striking enough to warrant attention. Within six months, 54 percent of patients reported some relief. By the final check-in, two-thirds had experienced fewer flares, and 60 percent said they were in less pain. These are meaningful improvements for a condition that can severely disrupt daily life.

The mechanism appears to work on two fronts, according to dermatologists examining the findings. Dr. Brendan Camp, a New York-based skin specialist, explained that weight loss itself reduces what he called "mechanical friction"—the constant rubbing and pressure that aggravates hidradenitis suppurativa in skin folds. Beyond that, the drugs appear to have their own anti-inflammatory properties that may help the skin heal and prevent new flares from forming. The combination of shedding pounds and the medication's direct effect on inflammation creates a dual benefit that neither approach alone might achieve.

Yet the caution in the medical community is real and warranted. Camp was careful to note that the study's design—retrospective rather than a controlled trial—limits how confidently doctors can draw conclusions. The participants were not a representative sample of everyone with hidradenitis suppurativa; they were predominantly obese and diabetic. It remains unclear whether the same benefits would appear in patients who are lean or who don't have diabetes. The drugs themselves carry side effects, can be expensive, and are not approved by regulators for treating skin conditions. Using them off-label for hidradenitis suppurativa is not standard practice and would require careful consideration.

Camp's recommendation is straightforward: patients interested in exploring this possibility should consult both their dermatologist and the physician prescribing the GLP-1 medication. The conversation needs to weigh the potential benefits against the known risks, the cost, and the reality that we don't yet have definitive evidence from a large, well-controlled trial. For someone suffering from a painful chronic skin condition, the promise is real. But so is the need for medical guidance and realistic expectations. The findings hint at a future where these drugs might serve a dual purpose—managing weight while easing one of dermatology's most difficult chronic conditions—but that future is not yet here.